Limited Competition: NIGMS Mature Synchrotron Resources for Structural Biology (P30 - Clinical Trial Not Allowed) | PAR 22 166

Opportunity Information: Apply for PAR 22 166

This NIH grant opportunity, PAR-22-166, is a limited-competition funding announcement from the National Institute of General Medical Sciences (NIGMS) that supports established (or "mature") synchrotron-based structural biology resources through the P30 center grant mechanism. The central purpose is to keep proven synchrotron X-ray beamline resources operating at a high level so they can reliably serve the broader biomedical research community. In practical terms, the program is designed to fund the ongoing operations, upkeep, and user-facing services of beamlines that already provide structural biology capabilities, rather than launching brand-new experimental platforms or underwriting major, high-risk technology inventions.

A key feature of the announcement is what NIGMS means by "mature." The beamline methods and capabilities proposed for support are expected to be well established, routinely used, and stable enough that they do not require significant new technology development to be useful. The goal is not to fund a beamline as a test bed for unproven approaches, but to maintain and refine reliable infrastructure that many scientists can depend on. That does not mean the resource must remain static. The FOA anticipates that the facility will be maintained and, where appropriate, upgraded in line with current best practices so the beamlines remain state-of-the-art in terms of performance, reliability, throughput, data quality, and user experience.

The program is also intentionally narrow in who can apply. It is limited to synchrotron structural biology resources whose operations recently have been, or currently are being, supported by NIGMS. That limitation reflects a continuity-and-stewardship model: the institute is focusing on resources it has already invested in and that are already integrated into the national structural biology ecosystem. In other words, this is not an open call for any synchrotron facility to start a new beamline program; it is meant to sustain existing NIGMS-supported beamline resources that have demonstrated utility and have an established user community.

From a service perspective, the FOA emphasizes broad access to X-ray beamlines for structural biology research. Applicants are expected to run the beamlines as shared resources that enable outside investigators to collect high-quality diffraction data and related measurements needed for structure determination and structural analysis. Alongside maintaining technical capabilities, the resource is expected to actively communicate its availability and strengths to the biomedical research community. That includes outreach activities that make potential users aware of what the beamlines can do, how to apply for access, what kinds of samples and experiments are supported, and what the expectations are for scheduling, data handling, and acknowledgement policies.

User support is a major expectation under this opportunity. The announcement highlights training and assistance as core responsibilities of the funded resource, which generally implies staff expertise to help users design feasible experiments, prepare for beam time, operate instrumentation and software workflows, troubleshoot common problems, and manage data collection and processing. This user-centric focus fits the P30 resource model, where the success of the program is often measured by how well it enables high-quality science across many external projects, rather than by a single lab's research agenda.

Administratively, this is a discretionary grant opportunity under the NIH, classified within the health funding activity category and associated with CFDA number 93.859. The funding instrument is a grant, and the mechanism is P30. The FOA is explicitly labeled "Clinical Trial Not Allowed," meaning the supported activities are not intended to include clinical trials as defined by NIH. The original closing date listed for the opportunity is 2024-10-10.

Eligibility rules include explicit restrictions on foreign involvement. Non-U.S. (non-domestic) entities are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible. In addition, foreign components, as NIH defines them in the NIH Grants Policy Statement, are not permitted. The listing also notes "Small businesses" under eligible applicants, though in practice applicants should rely on the full FOA language and NIH eligibility guidance to confirm organizational eligibility and any constraints tied to the limited-competition requirement (namely, prior or current NIGMS support of the resource). The bottom line is that the opportunity is aimed at sustaining proven, NIGMS-backed synchrotron structural biology beamline resources that deliver dependable access, modernized operations, strong outreach, and hands-on user training and support to the U.S. biomedical research community.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Limited Competition: NIGMS Mature Synchrotron Resources for Structural Biology (P30 - Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.859.
• This funding opportunity was created on 2022-04-19.
• Applicants must submit their applications by 2024-10-10. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: Small businesses.

Apply for PAR 22 166

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: